Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Teleflex	NovoCure	Insulet	Abiomed	Fresenius SE & Co. KGaA
Symbol	NYSE:TFX	NASDAQ:NVCR	NASDAQ:PODD	NASDAQ:ABMD	OTCMKTS:FSNUY
Price Information
Current Price	$393.00	$179.27	$232.42	$268.56	$13.73
52 Week Range	Buy	Hold	Hold	Hold	Buy
MarketRank™
Overall Score	2.0	1.6	1.6	1.8	1.4
Analysis Score	2.6	2.2	3.2	3.1	0.0
Community Score	2.3	2.5	2.7	2.6	2.3
Dividend Score	1.7	0.0	0.0	0.0	1.7
Ownership Score	1.7	1.7	0.0	1.7	0.0
Earnings & Valuation Score	1.9	1.9	1.9	1.9	3.1
Analyst Ratings
Consensus Recommendation	Buy	Hold	Hold	Hold	Buy
Consensus Price Target	$460.44	$195.71	$263.85	$348.33	N/A
% Upside from Price Target	17.16% upside	9.17% upside	13.52% upside	29.70% upside	N/A
Trade Information
Market Cap	$18.32 billion	$17.89 billion	$14.98 billion	$11.88 billion	$29.69 billion
Beta	1.14	1.29	0.76	1.41	1.36
Average Volume	204,936	950,268	507,876	314,635	31,148
Sales & Book Value
Annual Revenue	$2.60 billion	$351.32 million	$738.20 million	$840.88 million	$39.66 billion
Price / Sales	7.08	52.77	20.87	14.45	0.77
Cashflow	$15.87 per share	N/A	$0.55 per share	$4.30 per share	$2.54 per share
Price / Cash	24.77	N/A	423.20	62.52	5.40
Book Value	$64.35 per share	$2.20 per share	$1.23 per share	$23.64 per share	$13.38 per share
Price / Book	6.11	81.49	188.96	11.36	1.03
Profitability
Net Income	$461.47 million	$-7,230,000.00	$11.60 million	$203.01 million	$2.11 billion
EPS	$11.15	($0.07)	$0.19	$4.74	$0.94
Trailing P/E Ratio	50.58	943.58	528.24	59.02	15.09
Forward P/E Ratio	31.14	416.91	211.29	55.15	13.20
P/E Growth	2.63	N/A	N/A	4.15	N/A
Net Margins	14.66%	4.26%	3.33%	25.89%	4.99%
Return on Equity (ROE)	16.33%	7.40%	8.94%	15.34%	6.74%
Return on Assets (ROA)	7.66%	3.94%	2.07%	13.51%	2.63%
Dividend
Annual Payout	$1.36	N/A	N/A	N/A	$0.17
Dividend Yield	0.35%	N/A	N/A	N/A	1.24%
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	12.20%	N/A	N/A	N/A	18.09%
Years of Consecutive Dividend Growth	1 Years	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.63%	N/A	1.55%	N/A	0.68%
Current Ratio	2.99%	4.02%	6.62%	6.81%	1.21%
Quick Ratio	1.88%	3.74%	5.91%	6.02%	0.92%
Ownership Information
Institutional Ownership Percentage	89.78%	71.09%	N/A	93.95%	0.06%
Insider Ownership Percentage	2.21%	5.07%	1.10%	3.40%	N/A
Miscellaneous
Employees	14,000	1,023	1,900	1,536	311,269
Shares Outstanding	46.73 million	103.41 million	66.27 million	45.23 million	2.23 billion
Next Earnings Date	7/29/2021 (Estimated)	7/29/2021 (Estimated)	8/5/2021 (Estimated)	8/5/2021 (Estimated)	7/29/2021 (Estimated)
Optionable	Optionable	Optionable	Optionable	Optionable	Not Optionable

Source	Headline
	Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Hits New 52-Week High at $13.42 americanbankingnews.com - May 13 at 7:48 PM
	DZ Bank Reaffirms Buy Rating for Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) americanbankingnews.com - May 12 at 12:10 PM
	Germany stocks mixed at close of trade; DAX up 0.02% investing.com - May 10 at 2:50 PM
	Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Announces Quarterly Earnings Results americanbankingnews.com - May 7 at 2:57 PM
	Fresenius Q1 Net Income Before Special Items Declines; Confirms FY21 Guidance nasdaq.com - May 6 at 2:30 AM
	Fresenius-Aktie: Dritter Tag mit Gewinnen - Dax kann Fresenius nicht davonziehen welt.de - May 5 at 11:16 AM
	Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Given Average Rating of "Buy" by Brokerages americanbankingnews.com - May 5 at 6:40 AM
	Fresenius SE & Co. KGaA buy Kirus sharewise.com - May 4 at 5:45 PM
	Fresenius-Aktie: Sechster Tag ohne Veränderung - Dax und Fresenius auf einer Linie welt.de - May 3 at 11:42 AM
	Fresenius-Aktie: Kurs erholt sich - Fresenius läuft besser als Dax welt.de - May 1 at 4:22 PM
	Germany stocks mixed at close of trade; DAX down 0.12% investing.com - April 30 at 12:53 PM
	Barclays senkt Ziel für Fresenius SE auf 50 Euro - 'Overweight' t-online.de - April 29 at 10:10 AM
	Fresenius SE-Aktie aktuell: Fresenius SE mit grünen Vorzeichen finanzen.net - April 29 at 10:10 AM
	Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Short Interest Update americanbankingnews.com - April 28 at 7:10 PM
	Fresenius SE & Co. KGaA's (FSNUY) Overweight Rating Reiterated at Barclays americanbankingnews.com - April 28 at 5:32 PM
	Fresenius-Aktie: Gleichbleibend - Fresenius kann mit Dax nicht mithalten welt.de - April 16 at 7:27 PM
	Total Fluid Management Market Size 2021 Research Report including Industry Segment by Type, Historical Data and Market Forecast to 2026 - MarketWatch marketwatch.com - April 16 at 2:26 PM
	Fresenius-Aktie: Ohne Veränderung - Fast Gleichstand bei Dax und Fresenius welt.de - April 15 at 10:45 AM
	Fresenius-Aktie: Es geht wieder bergab - Fresenius kann mit Dax nicht mithalten welt.de - April 15 at 10:45 AM
	Fresenius SE-Aktie aktuell: Fresenius SE präsentiert sich stärker finanzen.net - April 11 at 2:34 PM
	Fresenius-Aktie: Unternehmen erholt sich - Dax hinter Fresenius zurück welt.de - April 9 at 5:53 PM
	Germany stocks higher at close of trade; DAX up 0.21% investing.com - April 9 at 12:52 PM
	Fitch Affirms Fresenius SE at 'BBB-'; Outlook Stable fitchratings.com - April 6 at 7:31 PM
	Fresenius SE KGaA Stock Is Believed To Be Modestly Undervalued gurufocus.com - April 1 at 1:46 PM
	Fresenius-Aktie: Gleichbleibend - Fast Gleichstand bei Dax und Fresenius welt.de - March 23 at 12:54 PM

Date	Company	Brokerage	Action
5/6/2021	Teleflex	Morgan Stanley	Boost Price Target
5/6/2021	Teleflex	SVB Leerink	Boost Price Target
3/18/2021	Teleflex	Raymond James	Boost Price Target
2/25/2021	Teleflex	Piper Sandler	Reiterated Rating
1/27/2021	Teleflex	JMP Securities	Boost Price Target
1/11/2021	Teleflex	Wells Fargo & Company	Boost Price Target
1/8/2021	Teleflex	KeyCorp	Boost Price Target
1/6/2021	Teleflex	Needham & Company LLC	Boost Price Target
12/15/2020	Teleflex	UBS Group	Boost Price Target
4/26/2021	NovoCure	Truist Securities	Boost Price Target
4/20/2021	NovoCure	Wedbush	Reiterated Rating
4/20/2021	NovoCure	Mizuho	Boost Price Target
4/20/2021	NovoCure	Northland Securities	Boost Price Target
8/3/2020	NovoCure	SunTrust Banks	Reiterated Rating
7/30/2020	NovoCure	Oppenheimer	Reiterated Rating
5/7/2021	Insulet	BTIG Research	Reiterated Rating
3/25/2021	Insulet	Canaccord Genuity	Upgrade
12/16/2020	Insulet	Smith Barney Citigroup	Downgrade
12/16/2020	Insulet	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Downgrade
7/13/2020	Abiomed	OTR Global	Upgrade
3/23/2020	Abiomed	Stephens	Lower Price Target
9/30/2019	Abiomed	William Blair	Reiterated Rating
8/2/2019	Abiomed	Guggenheim	Downgrade
5/12/2021	Fresenius SE & Co. KGaA	DZ Bank	Reiterated Rating
4/28/2021	Fresenius SE & Co. KGaA	Barclays	Reiterated Rating
2/19/2021	Fresenius SE & Co. KGaA	Berenberg Bank	Reiterated Rating
2/10/2021	Fresenius SE & Co. KGaA	JPMorgan Chase & Co.	Reiterated Rating
2/4/2021	Fresenius SE & Co. KGaA	Deutsche Bank Aktiengesellschaft	Downgrade
1/6/2021	Fresenius SE & Co. KGaA	Nord/LB	Reiterated Rating
12/3/2020	Fresenius SE & Co. KGaA	Bank of America	Downgrade
8/5/2020	Fresenius SE & Co. KGaA	Jefferies Financial Group	Downgrade
3/24/2020	Fresenius SE & Co. KGaA	Sanford C. Bernstein	Upgrade
3/22/2019	Fresenius SE & Co. KGaA	The Goldman Sachs Group	Reiterated Rating

(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources